Tag Archives: Edward White

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS) and Unum Therapeutics Inc (NASDAQ: UMRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clovis Oncology (CLVS – Research Report) and Unum Therapeutics Inc (UMRX – Research Report) with bullish sentiments. Clovis Oncology (CLVS) In a

H.C. Wainwright Keeps a Buy Rating on Acceleron Pharma (XLRN)

H.C. Wainwright analyst Edward White maintained a Buy rating on Acceleron Pharma (XLRN – Research Report) today and set a price target of $69. The company’s shares opened today at $40.09. White said: “Our $69 price target is based on

H.C. Wainwright Maintains a Buy Rating on Aeglea Biotherapeutics Inc (AGLE)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aeglea Biotherapeutics Inc (AGLE – Research Report), with a price target of $20. The company’s shares opened today at $6.23, close to its 52-week low

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS), CytomX Therapeutics Inc (NASDAQ: CTMX) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS – Research Report), CytomX Therapeutics Inc (CTMX – Research Report) and Aslan Pharmaceuticals Ltd (ASLN – Research Report) with

Aeglea Biotherapeutics Inc (AGLE) Has a New Rating from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Aeglea Biotherapeutics Inc (AGLE – Research Report) and a price target of $20. The company’s shares closed yesterday at $6.50, close to its

H.C. Wainwright Thinks Clovis Oncology’s Stock is Going to Recover

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS – Research Report), with a price target of $36. The company’s shares closed yesterday at $16.36, close to its 52-week low of